Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes

INTRODUCTION: Rapid-acting therapies remain an unmet need in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone (ZRN) is being evaluated as a once-daily, oral, 14-day treatment for adult patients with MDD and PPD. OBJECTIVES: To evaluate the efficacy (assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Clayton, A. H., Deligiannidis, K. M., Ramos-Quiroga, J. A., Lasser, R., Sankoh, A. J., Leclair, B., Kotecha, M., Doherty, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596067/
http://dx.doi.org/10.1192/j.eurpsy.2023.276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596067/
http://dx.doi.org/10.1192/j.eurpsy.2023.276

Ejemplares similares